Events FDA Immunization 
Drug Topics
JUNE 19, 2025
The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The medication is expected to launch in July 2025.
Drug Topics
JULY 21, 2025
The FDA approved insulin aspart-xjhz (Kirsty) 100 units/mL as the first and only interchangeable biosimilar to insulin aspart (NovoLog). 1 The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
AUGUST 4, 2025
They're providing clinical advice, testing, immunizations, and many other necessary services to maintain good health. Pharmacy closures have become commonplace within the industry as of late, with thousands of shutdowns since 2010 and a trend that’s showing significantly more pharmacy closures than openings.
Drug Topics
JUNE 9, 2025
The FDA approved telmisartan, amlodipine and indapamide (Widaplik) for the treatment of hypertension in adult patients, George Medicines said in a release. The FDA approved telmisartan, amlodipine and indapamide (Widaplik) for the treatment of hypertension in adult patients, George Medicines said in a release.
Drug Topics
JULY 2, 2025
She highlighted the challenges of maintaining accurate, transparent vaccine guidance, focusing on the importance of trusted health care providers helping patients understand immunization strategies.
Drug Topics
JULY 11, 2025
In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. Increasing pneumococcal vaccine uptake is especially important in light of the recent COVID-19 pandemic that disrupted routine immunization services and highlighted the vulnerability of adults to respiratory infections.”
Drug Topics
JULY 16, 2025
The primary outcomes included the number of individuals with HIV, the number of patients who experienced at least 1 adverse event (AE), and the number of participants who discontinued the study due to AEs.
Expert insights. Personalized for you.
Let's personalize your content